An interventional study of reduction of risperidone, haloperidol, olanzapine, quetiapine, aripiprazole, paliperidone, levomepromazine, perphenazine in Schizophrenia Relapse, sponsored by Juntendo University. Completed. Open to participants aged 20 Years to 70 Years. Per ClinicalTrials.gov, last updated 2021-09-09.
Sponsored by Juntendo University · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
To reduce antipsychotics to under 1000mg in patients with schizophrenia taking more than 1000mg/day and to evaluate relationship between relapse and cognitive function.
We attempted to reduce the dose of antipsychotics to ≤1000-mg chlorpromazine eq./day. The dose was gradually reduced at a rate of ≤50-mg chlorpromazine eq./week, and the reduction was discontinued if the subjects relapsed. The differences in baseline cognitive function were analyzed between the patients with no relapse and relapse groups.
3,574 studies on the registry are indexed under Schizophrenia; 494 are open to participants now.
This study's enrollment of 139 is above the median of 70 across 2,952 interventional studies indexed under Schizophrenia.
Browse Schizophrenia studies →Juntendo University is the lead sponsor of 8 studies on the registry; 2 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
dose reduction of antipsychotics at a rate not exceeding 50mg chlorpromazine equivalent/week
Drug: reduction of risperidone, haloperidol, olanzapine, quetiapine, aripiprazole, paliperidone, levomepromazine, perphenazine
Number of Participants With Relapse
The definition of relapse is as follows 1.50% or greater increase in total DIEPSS score, 2. an increase in the total PANSS score of 25% or more from baseline, 3. deliberate self-injury, 4. emergence of clinically significant suicidal ideation, 5. violent behavior resulting in clinically significant injury to another person or property damage.
Time frame: One year after the baseline cognitive function test or three months after the end of dose reduction, whichever came first.
| Milestone | Dose Reduction |
|---|---|
| Started | 139 |
| Completed | 130 |
| Not completed | 9 |
The definition of relapse is as follows 1.50% or greater increase in total DIEPSS score, 2. an increase in the total PANSS score of 25% or more from baseline, 3. deliberate self-injury, 4. emergence of clinically significant suicidal ideation, 5. violent behavior resulting in clinically significant injury to another person or property damage.
| Participants | Dose Reduction |
|---|---|
| Number of Participants With Relapse | 130 |
Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Dose Reduction | — | 0/130 (0%) | 51/130 (39.2%) |
| Event | Dose Reduction |
|---|---|
| increase in the total PANSS score from baselinePsychiatric disorders | 51/130 |
| violent behaviorPsychiatric disorders | 15/130 |
| increase in total DIEPSS scorePsychiatric disorders | 0/130 |
| Age, Continuous(years) | Reduction Group |
|---|---|
| Mean | 51.5 ± 11.1 |
| Sex: Female, Male(Participants) | Reduction Group |
|---|---|
| Female | 50 |
| Male | 80 |
| Region of Enrollment(participants) | Reduction Group |
|---|---|
| Japan | 130 |
No study locations are listed for this record.
The record gives a start of Apr 2011, a primary completion of Jan 2017 and a completion of Jan 2017. It does not say whether these dates are actual or estimated.
Results were first posted in Sep 2021, 4 years 8 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Juntendo University